A
Agilent
Operates in the area of life sciences, diagnostics and applied chemical markets; a spinout from Hewlett Packard
About Agilent
Agilent Technologies operates in the electronic procurement services market, providing innovative solutions designed to streamline purchasing processes for businesses. The company offers a suite of eProcurement services that enable clients to load their pricing into their existing eProcurement platforms, access a hosted catalog, and utilize paperless transactions. Agilent's services are tailored to help businesses quickly and easily identify and purchase the specific products and supplies they need, ensuring the right price and ease of access. The company's business model focuses on enhancing productivity through increased automation, quicker connectivity, and simplified workflows, ultimately leading to lower costs and higher profitability for its clients. Agilent serves a diverse range of clients who rely on its expertise, reliability, consistency, and quality. The company generates revenue by providing these eProcurement solutions and leveraging its extensive product line.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Santa Clara, United States
- Listing
- IPO 1999
- Employees
- 18,271
- Open positions
- None listed
- Dealroom signal
- 46.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Chemistry, Became $1B as Subsidiary
- Technology
- Artificial Intelligence, Big Data, Machine Learning, Computer Vision, Recognition Technology, IoT InternetOfThings
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
- Investment activity
- 74 companies, latest Jul 2026
- Capital deployed
- $1.1B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2026 | $600M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Sep 2019 | $500M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Agilent is 1.1M monthly website visits, down 15.4% over the last three months. Agilent's team grew 14.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
HALO X-ray TechnologiesNottingham, United KingdomDeveloping X‑ray diffraction screening systems that integrate with existing CT scanners for aviation, postal and customs security, with medical system applications
→
Biocare MedicalPacheco, United StatesAntibodies, reagents, and automated lab instruments used in cancer diagnostics and biomedical research
$950Mvaluation
BioTek InstrumentsWinooski, United StatesLife science laboratory instruments, including microplate readers, imaging systems, and automation tools for biomedical research
$1.2Bvaluation
BioVectraCharlottetown, CanadaBioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients
$915Mvaluation
sigSense TechnologiesOakland, United StatesHelping labs run better, faster, and cheaper by providing a comprehensive picture of lab operations
→
RareCyteSeattle, United StatesLife science research and diagnostic development company focused on characterizing and isolating rare cells in the blood
$120Mvaluation
ElegenSan Carlos, United StatesElegen is a biotechnology company that develops microfluidic technology
$140Mvaluation
BiofidelityCambridge, United KingdomRapid genomic biomarker detection for precision oncology
$96Mvaluation
E-msionCorvallis, United States
→
Avida BiomedFremont, United States
→
PSS Polymer Standards ServiceBristol, United StatesPSS Perfect Separation Solutions
→
Halo LabsBurlingame, United StatesHelping customers reduce development time and improve patient safety by quantifying stability, purity, and quality in protein therapeutics and cell and gene therapy products
$60Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
HP
Other known investors4 additional known investors
Current
EPFL Innovation Park
Nesta Impact Investments
Pivot Park
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Agilent on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Agilent’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.